Would you give your CDMO a 10/10 for overall satisfaction? Data from ISR’s Biologic API and Biologic Drug Product CMO Quality Benchmarking reports show only 3 percent of service interactions result in top scores. Learn what made some biologic outsourcers very satisfied with their CDMO experience and what these sponsor-CDMO relationships have in common.
Industry Standard Research explains how Life Science Leader’s CMO Leadership Awards and the corresponding market research data can be used by biopharma companies to make more informed CMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.
A deal between firms is necessarily an alignment of interests, at least over the term of the deal. There should be no expectation that the interests of two firms will be constant over time or that they will always be able to make a deal or collaborate.
The revolution in scientific knowledge that is bringing hope to patients with devastating diseases is also setting the stage for modernizing our approach to specifications and process control. Updating our approach to specification setting will accelerate the delivery of breakthroughs to patients.